# Study of MHB088C for Patients With Advanced Solid Malignant Tumors

> **NCT07102004** · PHASE1,PHASE2 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 515 (estimated)

## Conditions studied

- Advanced/Metastatic Solid Tumors

## Interventions

- **DRUG:** MHB088C for Injection

## Key facts

- **NCT ID:** NCT07102004
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-20
- **Primary completion:** 2026-07
- **Final completion:** 2027-07
- **Target enrollment:** 515 (ESTIMATED)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07102004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07102004, "Study of MHB088C for Patients With Advanced Solid Malignant Tumors". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07102004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*